Immunotherapy such as PD-1/PD-L1 inhibitors holds great promise as therapeutic approach for various cancers, however, current evidence [67], albeit still preliminary, suggests a limited effect of immunotherapy on early-stage lung cancer manifested as GGN. Here, PDCD1 is linked to cancer.